Clinical trial
Investigation of Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Multiple Doses of Somapacitan in Subjects With Mild and Moderate Degrees of Hepatic Impairment Compared to Subjects With Normal Hepatic Function
NCT03212131 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Investigation of Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Multiple Doses of Somapacitan in Subjects With Mild and Moderate Degrees of Hepatic Impairment Compared to Subjects With Normal Hepatic Function
- Lead sponsor
- Novo Nordisk A/S
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- August 16, 2017
- Completion date
- March 8, 2018
- Enrollment
- 34 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
adult growth hormone deficiency, growth hormone deficiency in children, growth hormone disorder